Hip Replacement Outperforms Exercise Therapy Alone

What Did the Hip Replacement Trial Actually Find?

The randomized controlled trial enrolled adults with moderate-to-severe hip osteoarthritis and assigned them to either total hip arthroplasty or a supervised exercise program. After one year, the surgical group showed clinically meaningful gains across validated outcome measures including pain intensity, walking ability, and hip-specific function scores. The exercise-only cohort improved modestly but did not approach the magnitude of benefit observed after joint replacement.

The findings carry weight because head-to-head trials comparing surgery against non-operative care are rare in orthopedics. Most evidence to date has come from observational cohorts, where selection bias makes it difficult to determine whether surgery itself drives the improvement. By randomizing patients, the Finnish team isolated the independent effect of the prosthesis itself, providing the strongest causal evidence to date in this population.

How Does This Change the Stepped-Care Approach to Hip Arthritis?

Major orthopedic societies including the American Academy of Orthopaedic Surgeons and the European Alliance of Associations for Rheumatology generally endorse a stepped-care model: lifestyle modification and physical therapy come first, with arthroplasty reserved for patients who fail conservative treatment. This trial does not overturn that framework for mild disease, but it challenges the assumption that prolonged non-operative trials are appropriate once symptoms reach the moderate-to-severe range.

Clinically, the implication is that patients with significant joint destruction, persistent pain, and functional limitation may benefit from earlier surgical referral rather than extended physiotherapy programs that produce only marginal gains. Health systems will need to weigh this against capacity constraints, since hip replacement waiting lists are already long in many countries. Cost-effectiveness analyses will likely follow, given that arthroplasty carries upfront expense but may reduce long-term disability, opioid use, and lost productivity.

What Are the Risks and Limitations of Hip Arthroplasty?

Modern total hip arthroplasty is one of the most successful procedures in medicine, with implant survival rates exceeding 90 percent at 15 years according to national joint registries in Sweden, the UK, and Australia. Nonetheless, complications occur. Periprosthetic infection affects roughly 1 percent of primary hip replacements and is difficult to treat. Venous thromboembolism, dislocation, and periprosthetic fracture are other recognized risks. Younger, more active patients face higher lifetime revision rates as bearings wear.

The Finnish trial does not eliminate these considerations. What it does is clarify the magnitude of expected benefit, which patients and surgeons can now weigh more confidently against individual risk profiles. Shared decision-making remains essential, particularly for patients with significant cardiovascular disease, frailty, or limited rehabilitation potential. The trial's one-year horizon also leaves longer-term comparative durability questions open.